In short, stereotactic radiotherapy combined with TP chemotherapy could significantly improve the clinical efficacy of NSCLC treatment and the levels of CYFRA21-1 and MALAT1 in blood of patients. Here, MALAT1 is linked to non-small cell lung carcinoma.